HC Wainwright Reaffirms “Buy” Rating for Barinthus Biotherapeutics (NASDAQ:BRNS)

HC Wainwright reissued their buy rating on shares of Barinthus Biotherapeutics (NASDAQ:BRNS) in a research report sent to investors on Monday morning, Benzinga reports. They currently have a $5.00 price objective on the stock. HC Wainwright also issued estimates for Barinthus Biotherapeutics’ Q3 2024 earnings at ($0.49) EPS, Q4 2024 earnings at ($0.49) EPS, FY2024 earnings at ($1.82) EPS, Q1 2025 earnings at ($0.48) EPS, Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.47) EPS and FY2025 earnings at ($1.89) EPS.

Other equities analysts have also recently issued reports about the stock. Barclays dropped their price objective on shares of Barinthus Biotherapeutics from $7.00 to $3.00 and set an overweight rating on the stock in a research note on Thursday, June 13th. William Blair reissued an outperform rating on shares of Barinthus Biotherapeutics in a report on Thursday, June 13th.

Barinthus Biotherapeutics Trading Down 1.5 %

BRNS stock opened at $1.30 on Monday. The business has a 50 day simple moving average of $1.49 and a 200-day simple moving average of $2.17. The company has a market capitalization of $50.75 million, a P/E ratio of -0.71 and a beta of -0.52. Barinthus Biotherapeutics has a twelve month low of $1.21 and a twelve month high of $5.10.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its earnings results on Thursday, August 8th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.01). Research analysts predict that Barinthus Biotherapeutics will post -1.9 EPS for the current fiscal year.

Institutional Investors Weigh In On Barinthus Biotherapeutics

Several institutional investors have recently made changes to their positions in the stock. DC Funds LP purchased a new position in shares of Barinthus Biotherapeutics in the 1st quarter valued at about $1,528,000. BlueCrest Capital Management Ltd acquired a new position in Barinthus Biotherapeutics during the first quarter worth $1,292,000. M&G Plc acquired a new position in Barinthus Biotherapeutics during the second quarter worth $7,276,000. Ipswich Investment Management Co. Inc. acquired a new stake in Barinthus Biotherapeutics in the second quarter valued at $32,000. Finally, Catalina Capital Group LLC purchased a new position in shares of Barinthus Biotherapeutics in the second quarter valued at $25,000. 25.20% of the stock is currently owned by hedge funds and other institutional investors.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.